X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
STUP-001 (AAV-based gene therapy), the innovative GT medication, unties the knot for spinal cord injured patient through motor sensory neuron reprogramming technology. Cell fate conversion using virus transduction system is of great interest in the field of Gene Therapy.
Lead Product(s): AAV-Based Gene Therapy
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: STUP-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Stand Up Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 29, 2022
Details:
The company intends to use the funds to promote the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Legend Capital
Deal Size: $56.1 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 20, 2022
Details:
The adeno-associated virus (AAV) based drug, LTGT06, was developed by Lantu with crucial support from VectorBuilder. The trial subject was a three-year-old boy whose father gained worldwide attention for not giving up on his son.
Lead Product(s): LTGT06
Therapeutic Area: Genetic Disease Product Name: LTGT06
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lantu Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
